Plasma NT1-tau and Aβ
Alzheimer disease
Aβ
Down syndrome
biomarker
plasma
tau
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
12 Jul 2023
12 Jul 2023
Historique:
revised:
09
06
2023
received:
24
02
2023
accepted:
12
06
2023
medline:
13
7
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
aheadofprint
Résumé
People with Down syndrome (DS) often develop Alzheimer's disease (AD). Here, we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment. Plasma NT1-tau, Aβ Discovery cohort linear mixed models for NT1-tau, Aβ NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : P30 AG072946
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001857
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD064993
Pays : United States
Organisme : NIH HHS
ID : U01 AG051412
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG068054
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG014673
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD087011
Pays : United States
Organisme : NIH HHS
ID : U01 AG051406
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005133
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001414
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002373
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD065160
Pays : United States
Organisme : NIH HHS
ID : R01 HD065160
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG051406
Pays : United States
Organisme : NICHD NIH HHS
ID : P01 HD035897
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIH HHS
ID : R56 AG061837
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG061837
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG008702
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062715
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005681
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : NIH HHS
ID : R01 AG021912
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG051412
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090256
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066519
Pays : United States
Organisme : NIH HHS
ID : P01 HD035897
Pays : United States
Organisme : NIH HHS
ID : U19 AG068054
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIH HHS
ID : AG014673
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Doran E, Keator D, Head E, et al. Down syndrome, partial trisomy 21, and absence of Alzheimer's Disease: the role of APP. J Alzheimers Dis. 2017;56:459-470.
Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol. 1998;43:380-383.
Mann DMA, Yates PO, Marcyniuk B, Ravindra CR. Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age: quantitative comparisons with younger Down's patients and patients with Alzheimer's disease. J Neurol Sci. 1987;80:79-89.
Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with down's syndrome: quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol. 1995;52:379-391.
Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988-1997.
Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17:860-869.
Startin CM, Ashton NJ, Hamburg S, et al. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimers Res Ther. 2019;11:26.
Schupf N, Zigman WB, Tang M-X, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75:1639-1644.
Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15:135-147.
Liu L, Kwak H, Lawton TL, et al. An ultra-sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma. Alzheimers Dement. 2022;18:1186-1202.
Liu L, Lauro BM, He A, et al. Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease. Alzheimers Dement. 2023;19:79-96.
Mengel D, Liu W, Glynn RJ, et al. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Alzheimers Res Ther. 2020;12:27.
Schupf N, Zigman WB, Tang M-X, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75:1639-1654.
Lleó A, Zetterberg H, Pegueroles J, et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nat Commun. 2021;12:4304.
Janelidze S, Christian BT, Price J, et al. Detection of brain tau pathology in down syndrome using plasma biomarkers. JAMA Neurol. 2022;79:797-807.
Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement. 2019;15:487-496.
Mengel D, Janelidze S, Glynn RJ, Liu W, Hansson O, Walsh DM. Plasma NT1 Tau is a specific and early marker of Alzheimer's disease. Ann Neurol. 2020;88:878-892.
Chhatwal JP, Schultz AP, Dang Y, et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat Commun. 2020;11:6024.
Handen BL, Lott IT, Christian BT, et al. The Alzheimer's biomarker consortium-down syndrome: rationale and methodology. Alzheimers Dement. 2020:12.
Evenhuis HM. Further evaluation of the dementia questionnaire for persons with mental retardation (DMR). J Intellect Disabil Res. 1996;40:369-373.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34:939-944.
Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21:249-258.
Liu L, Cai Y, Lauro BM, Meunier AL, Chhatwal J, Selkoe DJ. Generation and application of semi-synthetic p-Tau181 calibrator for immunoassay calibration. Biochem Biophys Res Commun. 2022;611:85-90.
O'Bryant SE, Petersen M, Hall J, Johnson LA. Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: important considerations for clinical trials and practice. Alzheimer's & Dementia. 2022;19:36-43. Portico. doi:10.1002/alz.12647
Berry K, Asken BM, Grab JD, et al. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology. Alzheimers Dement (Amst). 2022;14:e12321.
Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1-48.
Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1-26.
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26:379-386.
Coppus AMW, Schuur M, Vergeer J, et al. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging. 2012;33:1988-1994.
Head E, Doran E, Nistor M, et al. Plasma Amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimer's Dis. 2011;23:399-409.
Graff-Radford J, Mielke MM, Hofrenning EI, et al. Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. Neurobiol Aging. 2022;119:1-7.
Head E, Phelan MJ, Doran, et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017;5:93.
Lao PJ, Gutierrez J, Keator D, et al. Alzheimer-related cerebrovascular disease in Down syndrome. Ann Neurol. 2020;88:1165-1177.
Cullen NC, Janelidze S, Mattsson-Carlgren N, et al. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimers Dement. 2022;19(3):797-806.